NCT05886439View on ClinicalTrials.gov

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 11, 2023

Primary Completion Date

July 30, 2025

Study Completion Date

December 30, 2026

Conditions
Advanced Lung Carcinoma
Interventions
DRUG

LK101 injection (personlized neoantigen pulsed DC vaccine )

LK101 will be administered in a prime-boost schedule of 4 priming vaccination followed by 3 booster vaccinations.

DRUG

Pembrolizumab

Patients will receive pembrolizumab(200mg IV) Q3W until disease progression (PD), intolerable toxicity.

DRUG

Durvalumab

Patients will receive durvalumab (1500mg IV) Q3W until disease progression (PD), intolerable toxicity.

Trial Locations (1)

100021

RECRUITING

Cancer hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER